Your browser doesn't support javascript.
loading
French recommendations for the management of non-infectious chronic uveitis.
Quartier, P; Saadoun, D; Belot, A; Errera, M-H; Kaplanski, G; Kodjikian, L; Kone-Paut, I; Miceli-Richard, C; Monnet, D; Audouin-Pajot, C; Seve, P; Uettwiller, F; Weber, M; Bodaghi, B.
Afiliação
  • Quartier P; Pediatric Immunology, Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital, Assistance Publique-Hopitaux de Paris, Université de Paris, Paris, France. Electronic address: pierre.quartier@aphp.fr.
  • Saadoun D; Department of Internal Medicine and Clinical Immunology, RHU IMAP, Sorbonne University, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France. Electronic address: david.saadoun@aphp.fr.
  • Belot A; Department of Pediatric Nephrology, Rheumatology, Dermatology, Mère-Enfant Hospital, Hospices Civils de Lyon, Université Claude Bernard-Lyon 1, 69500 Bron, France.
  • Errera MH; Department of Ophthalmology, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France.
  • Kaplanski G; Department of Internal Medicine and Clinical Immunology, CHU La Conception, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.
  • Kodjikian L; Department of Ophthalmology, Hôpital universitaire de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
  • Kone-Paut I; Department of Pediatric Rheumatology, CHU de Bicêtre, APHP, University of Paris Saclay, Le Kremlin Bicetre, France.
  • Miceli-Richard C; Departement of rhumatology, Hôpital Cochin, Université de Paris, Paris, France.
  • Monnet D; Department of Ophthalmology, Université de Paris, Hôpital Cochin, Paris, France.
  • Audouin-Pajot C; Departement of rhumatology, Toulouse University Hospital (CHU de Toulouse), 330 Avenue de Grande-Bretagne, 31300 Toulouse, France.
  • Seve P; Department of Internal Medicine, Croix-Rousse University Hospital, Hospices Civils de Lyon, Université Claude Bernard-Lyon 1, 69004 Lyon, France.
  • Uettwiller F; Paediatric Rheumatology Unit, Centre Hospitalier Universitaire de Clocheville, Tours, France.
  • Weber M; Department of Ophthalmology, Centre Hospitalier Universitaire de Nantes, 44000 Nantes, France.
  • Bodaghi B; Departement of Ophthalmology, IHU FOReSIGHT, Sorbonne University, APHP, Paris, France. Electronic address: bahram.bodaghi@aphp.fr.
Rev Med Interne ; 44(5): 227-252, 2023 May.
Article em En | MEDLINE | ID: mdl-37147233
ABSTRACT
This French National Diagnostic and Care Protocol (NDPC) includes both pediatric and adult patients with non-infectious chronic uveitis (NICU) or non-infectious recurrent uveitis (NIRU). NICU is defined as uveitis that persists for at least 3 months or with frequent relapses occurring less than 3 months after cessation of treatment. NIRU is repeated episodes of uveitis separated by periods of inactivity of at least 3 months in the absence of treatment. Some of these NICU and NIRU are isolated. Others are associated with diseases that may affect various organs, such as uveitis associated with certain types of juvenile idiopathic arthritis, adult spondyloarthropathies or systemic diseases in children and adults such as Behçet's disease, granulomatoses or multiple sclerosis. The differential diagnoses of pseudo-uveitis, sometimes related to neoplasia, and uveitis of infectious origin are discussed, as well as the different forms of uveitis according to their main anatomical location (anterior, intermediate, posterior or panuveitis). We also describe the symptoms, known physiopathological mechanisms, useful complementary ophthalmological and extra-ophthalmological examinations, therapeutic management, monitoring and useful information on the risks associated with the disease or treatment. Finally, this protocol presents more general information on the care pathway, the professionals involved, patient associations, adaptations in the school or professional environment and other measures that may be implemented to manage the repercussions of these chronic diseases. Because local or systemic corticosteroids are usually necessary, these treatments and the risks associated with their prolonged use are the subject of particular attention and specific recommendations. The same information is provided for systemic immunomodulatory treatments, immunosuppressive drugs, sometimes including anti-TNFα antibodies or other biotherapies. Certain particularly important recommendations for patient management are highlighted in summary tables.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Uveíte / Síndrome de Behçet / Esclerose Múltipla Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline Limite: Adult / Child / Humans Idioma: En Revista: Rev Med Interne Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Uveíte / Síndrome de Behçet / Esclerose Múltipla Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline Limite: Adult / Child / Humans Idioma: En Revista: Rev Med Interne Ano de publicação: 2023 Tipo de documento: Article